ADC Therapeutics SA (ADCT)
Market Cap | 334.57M |
Revenue (ttm) | 68.62M |
Net Income (ttm) | -227.23M |
Shares Out | 82.81M |
EPS (ttm) | -2.77 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 638,637 |
Open | 4.230 |
Previous Close | 4.190 |
Day's Range | 3.800 - 4.280 |
52-Week Range | 0.360 - 6.040 |
Beta | 1.74 |
Analysts | Buy |
Price Target | 7.00 (+73.27%) |
Earnings Date | May 6, 2024 |
About ADCT
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to contin... [Read more]
Financial Performance
In 2023, ADCT's revenue was $69.56 million, a decrease of -66.86% compared to the previous year's $209.91 million. Losses were -$240.05 million, 52.8% more than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ADCT stock is "Buy." The 12-month stock price forecast is $7.0, which is an increase of 73.27% from the latest price.
News
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC...
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares...
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%) 1 compared to 1Q 2023
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient achieved a partial response with ZYNLONTA ®
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 147,600 of the Company'...
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patient...
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024, from ...
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settings
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggen...
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024, at 8:30 a....
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
Preclinical data support future clinical development of ADCs targeting Claudin-6 and NaPi2b Additional presentations include clinical and independent preclinical studies evaluating ADCT-601 targeting ...
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
LAUSANNE, Switzerland, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the TD Cowen 44...
Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth
The JPMorgan Healthcare Conference was likely just the beginning of another year of heightened interest and investments in ADC cancer drugs.
ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
LAUSANNE, Switzerland, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it received a notice from the New York Stock Exchange (NYSE) on January 2, 2024 that the ...
ADC Therapeutics Provides Business Updates
ZYNLONTA® 1 4Q 2023 net sales expected to be ~$16.5 million, a double-digit percentage increase as compared to 3Q 2023
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate
Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors
LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads bas...
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that th...
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
3Q 2023 ZYNLONTA® 1 net sales of $14.3 million reflect disruption following restructuring of commercial organization, increased competition and higher gross-to-net deductions
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferi...
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
Presentations to highlight clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
LAUSANNE, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30 a.m....
Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO
LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibo...
ADC Therapeutics to Participate in September Investor Conferences
LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in S...
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
LOTIS-5: Updated safety run-in results from Phase 3 trial demonstrate 80% ORR, 50% CR rate and median DoR of 8 months with no new safety signals